Product Description
A hormone made from testosterone in the prostate, testes, and certain other tissues. It is needed to develop and maintain male sex characteristics, such as facial hair, deep voice, and muscle growth. High amounts of androstanolone may increase the growth of prostate cancer and make it harder to treat. Also called DHT and dihydrotestosterone. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/androstanolone)
Mechanisms of Action: AR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Transdermal,Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: France | India | Slovenia | Taiwan | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Ascend
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Bone Cancer|Prostate Cancer|Pituitary Diseases|Hypothalamic Cancer|Hypogonadism|Skin Cancer|Bladder Cancer|Deficiency Diseases|Hypothalamic Diseases|Prostatic Diseases|Testicular Cancer|Protein Deficiency|Prostatic Hyperplasia|Testicular Diseases|Skin Diseases, Vascular|Pituitary Cancer|Pregnancy Outcomes|Vascular Cancer|Hypopituitarism|Inflammation|Breast Cancer
Phase 1: Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| IRB00015971 | P1 |
Terminated |
Prostate Cancer |
2013-03-01 |
2019-03-19 |
||
| FDHT - version 1, 9 March 2015 | P2 |
Terminated |
Prostate Cancer |
2018-09-15 |
2022-03-13 |
Treatments |
|
| [18F]FDHT PET in hormone naive prostate cancer | P2 |
Active, not recruiting |
Prostate Cancer|Bone Cancer |
2016-02-11 |
2022-03-13 |
Treatments |
|
| 2012-003981-42 | P2 |
Completed |
Breast Cancer |
2015-05-13 |
2025-07-09 |
Treatments |
|
| DHT-3 | P2 |
Completed |
Hypothalamic Diseases|Pituitary Cancer|Prostatic Hyperplasia|Bladder Cancer|Hypogonadism|Skin Diseases, Vascular|Testicular Diseases|Hypothalamic Cancer|Protein Deficiency|Pregnancy Outcomes|Inflammation|Vascular Cancer|Prostate Cancer|Testicular Cancer|Prostatic Diseases|Hypopituitarism|Deficiency Diseases|Skin Cancer|Pituitary Diseases |
2009-01-01 |
2019-03-21 |
Treatments |
|
| 03-DHT-01 | P2 |
Completed |
Hypogonadism |
2006-09-01 |
2022-08-16 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |